Upperton’s new Nottingham facility
18th January 2023 Upperton Pharma Solutions, a leading UK contract development and manufacturing organisation (CDMO), is delighted to announce that it has begun construction work for its new Development and GMP Manufacturing headquarters in Nottingham, UK. Working in close collaboration with its principal Design and Build contractor, T-SQUARED the team officially broke ground on the […]
Upperton Named Dual Winner at Medilink Midlands Awards, Underscoring Continued Growth and Commitment to Innovation
Upperton announces its recognition as winner of the Small Molecule Dosage Form category at the inaugural European CDMO Leadership Awards.
Risk Isn’t Inevitable: How the Right CDMO Partnership Protects Your Programme
What exactly is the difference between a CDMO, a CRO, and a CMO? Each plays a vital role in the life sciences ecosystem.
Hello world!
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Liquid Injectables: Stability Issues and How to Avoid Them
What exactly is the difference between a CDMO, a CRO, and a CMO? Each plays a vital role in the life sciences ecosystem.
How are Parenteral Manufacturing Solutions Evolving to Meet the Demands for More Specialised and Sensitive Drug Formulations?
What exactly is the difference between a CDMO, a CRO, and a CMO? Each plays a vital role in the life sciences ecosystem.
Upperton Advances Sterile Manufacturing Facility with MHRA Submission
Upperton advances sterile manufacturing facility following MHRA submission.
How Upperton Has Evolved to Meet the Changing Needs of Biotechs
What exactly is the difference between a CDMO, a CRO, and a CMO? Each plays a vital role in the life sciences ecosystem.
What Biotech Startups Need to Know About Sterile Fill-Finish Services
What exactly is the difference between a CDMO, a CRO, and a CMO? Each plays a vital role in the life sciences ecosystem.
Low Bioburden Powders for Terminal Sterilisation: Raising the Standard in Modern Drug Development
The pressure of speed to clinic is continuing to increase. Biotechs are under more pressure, and therefore the CDMOs supporting them must evolve too
DDL 2025 – The Next Chapter in Inhalation
• The pressure of speed to clinic is continuing to increase. Biotechs are under more pressure, and therefore the CDMOs supporting them must evolve too